All articles tagged with #weight loss
GLP-1 weight-loss medications may trigger changes in relationship dynamics after substantial weight loss, including increased autonomy and social activity that can strain partnerships; experts warn of a possible rise in separations or divorce as couples adjust, with reports of shifts in libido and intimacy. Some suggest couples therapy or undertaking the weight-loss journey together to mitigate the impact.
Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.
A large 23andMe GWAS of 27,885 GLP-1 med users links variants in GLP1R and GIPR to both weight-loss efficacy and nausea risk. A GLP1R missense variant (rs10305420) is associated with about 0.76 kg more weight loss per allele, while GIPR variants predict nausea specifically for tirzepatide (Zepbound/Mounjaro) but not semaglutide. 23andMe’s Total Health service now offers an interactive tool to estimate individual weight loss (roughly 6–20% of starting weight) and side-effect risk, moving toward precision obesity care where genetics is one piece of the puzzle though not the sole determinant.
In a Health Psychology study of 112 adults in a behavioral weight‑loss program, researchers found that eating the same meals and maintaining a consistent daily calorie intake led to greater weight loss than a highly varied diet. Each 100‑calorie daily fluctuation reduced weight loss by about 0.6%; participants who repeated more than half of their weekly foods lost about 5.9% of body weight versus 4.3% for those with a more varied diet. Additionally, those who logged higher weekend calories tended to lose more weight. The findings support building routines around go‑to meals, tracking intake for mindfulness and accountability, and rotating foods within groups to preserve enjoyment and gut diversity. GLP‑1 weight‑loss drugs exist and are popular, but behavioral strategies remain effective.
A retrospective study of 120 postmenopausal women found that adding menopausal hormone therapy to tirzepatide led to about 19.2% total body weight loss over roughly 18 months, versus 14% with tirzepatide alone, a statistically significant difference. The study is not randomized and did not distinguish hormone therapy types; researchers say controlled trials are needed to confirm the potential synergy and to explore cardiometabolic effects, building on prior work suggesting similar benefits with other GLP-1 drugs plus hormone therapy.
GLP-1 weight-loss injections can jump-start shedding pounds, but long-term success hinges on lifestyle: regular exercise, better food choices, adequate sleep, and attention to mental health. One patient lost 110 pounds after adding a six-days-a-week workout plan. Doctors warn about potential complications (pancreatitis, gallstones, kidney injury) if dosage is increased too quickly or misused, underscoring the need for medical supervision. Access and cost remain barriers, with limited insurance coverage for obesity and forthcoming Medicare coverage; online suppliers may lack dosing guidance and safety information.
A 48-year-old London hospitality PR reverses prediabetes after a lifestyle overhaul—swimming daily, cutting refined carbs and sugars, and reducing alcohol—losing weight from about 14.5 to 12 stone and returning blood sugar to normal within a year, showing that midlife fitness and diet changes can reverse the condition without sacrificing life’s pleasures.
Nara Lokesh reportedly shed nearly 13 kg through intermittent fasting (alternating between 16:8 and 18:6) and a one-meal-a-day plan, prompting discussion about balanced nutrition and the health implications of such regimes.
A Health Psychology study of 112 adults in a 12-week weight-loss program found that eating a low-variety, calorie-stable diet led to greater weight loss (about 5.9%) than more varied eating (about 4.3%). The research suggests routine meals can reduce decision fatigue and improve adherence, though long-term effects and individual preferences vary.
A Healthline study of 112 adults in a 12-week weight‑loss program found that participants who ate the same go‑to meals and kept calories steady lost more weight (average 5.9% of body weight) than those with a more varied diet (4.3%). The results show a correlation between dietary consistency and weight loss, though causation isn’t established and data were self‑reported within a highly structured program; the takeaway is that simplifying food choices and maintaining predictable calories may help some people lose weight.
New Health Psychology findings show adults in a 12-week weight-loss program who repeated meals and kept calories steady lost more weight (5.9% vs 4.3%) than those with varied diets. Greater day-to-day calorie consistency and dietary repetition predicted better results, while higher weekend calories tracked correlated with more weight loss—likely reflecting tracking honesty. The authors caution that the study shows correlation, not causation, and suggest simplifying choices with a rotation of go-to meals to combat decision fatigue in a challenging food environment.
Intermittent fasting (time-restricted eating and plans like 5:2) can reduce daily calories by about 200–500 kcal, which supports weight loss and may improve insulin sensitivity and brain fuel via ketones. Some evidence hints at diabetes remission in type 2 diabetes under fasting regimens, and longer fasts under medical supervision may reduce inflammation and boost metabolic resilience, but long-term safety remains uncertain. The benefits largely derive from calorie reduction rather than a magic effect of fasting; eight-hour windows simply make calorie restriction easier. Downsides include headaches, fatigue, sleep disruption, potential loss of fat-free mass if exercise is skipped, and risks for those with eating disorders, pregnant or breastfeeding, or diabetes without supervision. There is no conclusive evidence that fasting extends lifespan, and a one-size-fits-all approach does not apply.
A 52-week phase-3 trial in 1,698 adults with type 2 diabetes across six countries found orforglipron, a daily oral small-molecule GLP-1 drug, reduced HbA1c more and produced greater weight loss than oral semaglutide (1.71–1.91% vs 1.47% HbA1c and 6.1–8.2 kg vs 5.3 kg), but caused more gastrointestinal side effects and higher discontinuation (~10% vs 4–5%). It’s cheaper to manufacture and doesn’t require refrigeration, giving it logistical advantages, though long-term comparisons with injectable GLP-1 therapies and obesity trials without diabetes are still underway.
A Drexel University study of 112 overweight/obese adults in a behavioral weight-loss program found that those who ate the same meals daily and kept a consistent daily calorie intake lost more weight in the first 12 weeks (average 5.9% of body weight) than participants with a more varied diet (4.3%). The research used real-time food tracking and suggests routine eating can aid adherence, but it’s a small study that cannot prove causation and did not assess nutritional quality; more research is needed, and doctors should be consulted before changing diets.
Jen, 41, who shed 180 pounds on GLP-1, underwent an awake arm lift (brachioplasty) to remove excess skin—about four to five hours under local anesthesia with laughing gas—performed by Dr. Zachary Willis. She shared the journey on TikTok, says the experience wasn’t scary, and hopes to normalize weight-loss–related surgeries as awake options grow with GLP-1 use, with plans for a future awake breast lift.